雌激素通过调节Gα_s-cAMP通路减轻异丙肾上腺素导致的大鼠心肌损伤

本研究旨在通过给予去卵巢大鼠异丙肾上腺素制作心肌损伤及心功能异常模型,探讨雌激素通过调节兴奋性G(Gαs)蛋白-环磷酸腺苷(cAMP)信号通路纠正儿茶酚胺导致的心功能异常的机制。观察雌激素对大鼠血流动力学参数:左心室收缩峰压(LVSP)、左心室舒张末压(LVEDP)、左心室内压上升的最大变化速率(+dp/dtmax)、左心室内压下降的最大变化速率(-dp/dtmax),血浆脑尿钠肽(brain natriuretic peptide,BNP),cAMP浓度和心肌中Gαs蛋白表达的影响。结果显示:与假手术组相比,去卵巢大鼠的血流动力学参数、血浆BNP水平、血浆cAMP水平没有显著改变;但给予去卵巢大鼠异丙肾上腺素后,血流动力学参数LVSP、+dp/dtmax降低(P0.01),LVEDP、-dp/dtmax升高(P0.01),血浆BNP水平升高(P0.01),血浆cAMP水平降低(P0.01);而进一步的雌激素补充则改善了心功能:LVSP、+dp/dtmax升高(P0.01),LVEDP、-dp/dtmax降低(P0.05,P0.01),血浆BNP水平降低(P0.01),cAMP水平升高(P0.01);雌激素对Gαs蛋白表达没有显著影响。结果提示:雌激素对心肌损伤具有保护作用,升高cAMP水平,改善心肌收缩过度抑制,调节心脏的功能状态。     

大鼠下丘脑微量注射TRH对心功能的作用及其机制

目的：探讨下丘脑促甲状腺激素释放激素（TRH）对心功能活动的调节作用及其作用机制。方法：在SD大鼠下丘脑促垂体区埋管,微量注射TRH或预先注射一氧化氮合酶抑制剂L—NAME及M型乙酰胆碱受体阻断剂阿托品,记录给药前后左心室内压峰值（LVSP）、心率（HR）、室内压瞬时上升速率峰值（dp／dtmax）和瞬时下降速率峰值（-dp／dtmax）。结果：①与对照组相比,下丘脑促垂体区注射TRH可引起LVSP、HR、dp／dtmax及-dp／dtmax显著升高（P〈0．05或P〈0．01）。②单独注射L—NAME后只引起LVSP显著升高（P〈0．05或P〈0.01）,L-NAME预处理可抑制TRH引起的正向调节效应。③单独注射阿托品引起LVSP及dp／dtmax的显著升高（P〈0．05）,HR显著下降（P〈0．05）,阿托品预处理减弱了TRH加快心率和提高-dp／dtmax的效应。结论：①下丘脑TRH对心脏有正性变时、变力作用。②下丘脑内源性NO能降低LVSP,但对HR、dp／dtmax及-dp／dtmax明显影响,TRH的作用是经NO依赖通路的。③下丘脑内源性胆碱能递质对心脏有正性变时但负性变力的作用,下丘脑TRH调节心功能可能部分通过胆碱能M受体通路。     

实验性糖尿病心肌病大鼠模型建立及心脏功能和结构相关性分析

目的建立实验性糖尿病心肌病大鼠模型,观察心功能和结构变化,初步分析心脏功能和结构指标相关性。方法雄性Wistar大鼠随机分为正常对照组、高糖高脂膳食组和糖尿病心肌病模型组,采用高糖高脂膳食12周负荷一次性小剂量STZ腹腔注射建立糖尿病心肌病模型,观察各组动物心脏功能、心脏重量和心重指数、左心室形态和胶原含量等的变化。结果 (1)与正常对照组比较,糖尿病心肌病模型组大鼠左心室舒张末压(LVEDP)和最大舒张速率(-dp/dtmax)值显著升高(P0.05),心率(HR)、左心室收缩压(LVSP)、左心室最大收缩速率(+dp/dtmax)、每搏输出量(SV)和心排量(CO)明显降低(P0.05);全心重指数(HW/BW)和左心室重量指数(LVW/BW)明显升高(P0.01);常规HE染色显示心肌细胞排列紊乱,心肌细胞肥大,细胞核边缘不清等,室间隔和左心室壁厚度明显增加(P0.001,P0.05);心肌胶原含量明显增加(P0.05)。(2)大鼠心脏功能参数±dp/dtmax和CO值分别与结构参数HW/BW和LVW/BW呈现明显的相关性(P0.01或P0.05)。结论大鼠高糖高脂膳食喂养负荷小剂量STZ一次性腹腔注射,可造成心脏舒张和收缩功能紊乱以及心肌结构重塑,心脏功能与结构变化呈显著相关性,可复制实验性糖尿病心肌病模型。     

富硒板党对大鼠心肌缺血/再灌注损伤的保护作用及其机制

目的:研究富硒板党对大鼠心肌缺血/再灌注损伤的保护作用及其作用机制。方法:将32只大鼠随机分为假手术组、模型组、实验组和阳性对照组(n=8)。实验组术前按5.0 g/(kg·d)灌服富硒板党水溶液,阳性对照组按300 mg/(kg·d)灌服通心络胶囊,假手术组和模型组按5 ml/(kg·d)灌服生理盐水,连续给药14 d,参考Jonassen方法制作心肌缺血/再灌注模型,记录再灌注30 min内发生的的心律失常,并对室性心律失常(VA)进行量化评分,监测再灌注30 min时左室收缩压(LVSP)、左室舒张末压(LVEDP)、左室内压力上升最大速率(LV+dp/dtmax)及左室压力下降最大速率(LV-dp/dtmax),检测各组大鼠血清乳酸脱氢酶(LDH)、肌酸磷酸激酶(CK)、超氧化物歧化酶(SOD)的活性与丙二醛(MDA)的含量。结果:与与假手术组比,模型组大鼠LVSP、+dp/dtmax、-dp/dtmax显著降低,VA和LVEDP明显升高,血清LDH、CK活性显著增强,SOD活性显著降低,MDA含量明显增加(P0.01);与模型组比,实验组及阳性对照组大鼠LVSP、+dp/dtmax、-dp/dtmax显著升高,VA和LVEDP明显降低,血清LDH、CK活性显著降低,SOD活性显著增强,MDA含量明显减少(P0.01);与阳性对照组比,实验组大鼠VA、LVSP、+dp/dtmax、LVEDP-dp/dtmax和血清LDH、CK、SOD活性与MDA含量无显著性差异(P0.05)。结论:富硒板党对大鼠心肌缺血/再灌注损伤具有明显的保护作用,其作用机制与抗氧化损伤有一定关系。     

小鼠主动脉弓缩窄模型的建立及评价

目的通过显微外科技术建立小鼠主动脉弓缩窄压力超负荷模型,探讨心脏形态及功能变化的规律。方法135只雄性昆明小鼠随机分为主动脉弓缩窄组75只和假手术组60只。在术前、术后1周、4周、6周、8周1、2周进行高频心脏超声、血流动力学、心脏病理学检测,并对器官称重,对死亡原因进行分析。结果（1）主动脉弓缩窄手术成功率为88%;（2）与假手术组比较,术后4周,缩窄组小鼠出现左室向心性肥厚,左心室收缩期、舒张期后壁厚度（Pwsth;Pwdth）、左心室重量指数（LVMI）显著增加（P〈0.05）,术后6、8、12周上述指标呈轻度上升趋势;术后4、68、、12周,缩窄组小鼠动脉收缩压（SBP）、动脉舒张压（DBP）、左心室收缩压（LVSP）、左心室舒张末压（LVEDP）显著增加（P〈0.05）;术后8周,缩窄组小鼠表现为离心性肥厚,左心室收缩末期、舒张末期内径（LVESd;LVEDd）显著增加（P〈0.05）;术后12周,缩窄组小鼠出现失代偿性心力衰竭,左心室射血分数（EF%）、左心室压力上升和下降最大速率（dp/dtmax;dp/dtmin）显著降低（P〈0.05）,与8周缩窄组比较,12周缩窄组SBP、DBP、LVSP、LVEDP显著降低（P〈0.05）。结论通过主动脉弓缩窄,可以建立稳定的小鼠压力超负荷诱导左室向心性肥厚致心衰的动物模型,类似人类心肌肥厚向心衰发展的病理过程,是用于临床研究的一种较理想动物模型。     

一种大鼠急性心力衰竭动物模型的建立方法

目的 建立一种简便易行的大鼠急性心力衰竭动物模型复制方法.方法 选用体重280～350 g的雄性SD大鼠,麻醉后于舌下静脉快速推注盐酸普鲁帕酮注射液10.5 ,mg/kg,观察记录造模后1小时内动物心率、左心室内压最大上升速率( dp/dtmax)、左心室内压最大下降速率(-dp/dtmax).结果 大鼠造模后数秒内心率即显著减少, dp/dtmax显著下降,-dp/dtmax显著上升,持续数十分钟.与空白组比较有极显著性差异.参附注射液和白附片水煎液显著恢复模型动物心率、 dp/dtmax、-dp/dtmax,与模型组比较有显著性或极显著性差异.结论 采用普鲁帕酮注射液复制大鼠急性心阳虚衰动物模型是一种简便可靠的方法.     

慢性低氧对大鼠左右心室的功能及TRPC亚家族表达的影响

目的：探讨慢性低氧3周对大鼠左右心室的影响以及规范性瞬时感受器电位亚家族（TRPC）在慢性低氧诱导的右心室心肌肥厚中的表达。方法：将SD雄性大鼠48只随机分为对照组（CON组）和慢性低氧肺动脉高压模型组（CH组）（n=24）,CH组将大鼠置于连续的慢性低氧（10％±0．2％）环境饲养三周以诱导大鼠发生心肌肥厚。通过左、右心室插管法测定右心室内压（RVSP）、左心室内压（LVSP）、心率（HR）、平均体循环动脉压（mSAP）、左、右心室内压力最大上升速率（＋dp／dtmax）、最大下降速率（-dp／dkmax）、右心肥大指数（RVMI）、左心肥大指数（LVMI）;HE染色观察左、右心室心肌组织切片;通过SYBR Green荧光定量PCR法检测CON组、CH组大鼠的肥厚侧心室心肌组织编码TRPC 1／3／4／5／6／7的rnRNA表达;结合real-time RT-PCR结果对mRNA表达有显著变化的TRPC亚型通过免疫印迹法检测相应蛋白的表达。结果：与CON组相比：CH组的RVSP、RVMI、右心室±dp／dtmax显著增高（P〈0．01）,LVSP、左心室±dp／dmax无显著变化,LVMI显著降低（P〈0．01）;CH组右心室心肌细胞显著增粗（P〈0．01）,细胞内肌原纤维数量增多,心肌纤维排列紊乱,细胞核深染,形状不整;左心室心肌纤维无明显改变;CH组编码TRPCI的mRNA和蛋白显著增高（P〈0．05）,而编码其余TRPC亚型的mRNA无显著变化。结论：慢性低氧3周可特异性诱导sD大鼠产生右心室心肌肥厚,上调了编码右心室心肌细胞TRPCI通道蛋白的mRNA和蛋白的表达,TRPCI可能参与了心肌肥厚的发生发展。     

氧化苦参碱对急性心肌梗死家兔心功能和左心室重构的影响

目的:研究氧化苦参碱对急性心肌梗死家兔模型心功能及左心室重构的影响。方法:采用结扎家兔左前降支建立急性心肌梗死模型,随机分为3组(n=9):假手术组、模型组、氧化苦参碱组,假手术组不结扎冠状动脉。假手术组、模型组常规饲养,氧化苦参碱组在正常饲养基础上用灌胃给药氧化苦参碱1 ml/100 g,每日1次,分别在术后1周、4周观察氧化苦参碱对家兔左心室腔内直径(D)、心室重量指数(VWI)、心室重量(VW)、体重(BW)、心输出量(CO)和左心室收缩末期压(LVESP)、左心室舒张末期压(LVEDP)、左室内压变化率峰值(dp/dtmax)的影响。结果:与假手术组比较,模型组心脏游离左室壁梗死范围由粉红色变为深紫色。术后1周模型组与假手术组相比CO减少(P0.05),术后4周进一步减少(P0.01)。术后1周、4周氧化苦参碱组与模型组相比CO明显增加(P0.01),dp/dtmax增加(P0.05),LVESP明显升高(P0.01),LVEDP明显下降(P0.01);术后4周氧化苦参碱组与模型组相比,D明显减小(P0.01),VWI、VW减小(P0.05)。结论:氧化苦参碱能增加急性心肌梗死后心输出量,改善急性心肌梗死家兔左心室重构参数,改善心功能指标。     

丹酚酸B对大鼠离体工作心脏血流动力学的影响

目的 研究丹酚酸B对离体大鼠工作心脏血流动力学的影响.方法 采用Langendorff离体心脏灌流的方法,以左室内压( LVSP)、左室舒末压(LVEDP)、室内压最大上升速率(+dp/dtmax)、室内压最大下降速率(- dp/dtmax)、心率(HR)等血流动力学参数为指标,观察丹酚酸B对心肌收缩性能的影响.结果 不同剂量(10、5、2.5 mg/L)的丹酚酸B可使LVSP、±dp/dtmax明显升高,同时使HR减慢,并呈剂量依赖性,但对LVEDP无明显作用.结论 丹酚酸B对离体工作心脏有剂量依赖性正性肌力作用.     

大鼠心肌梗死后螺内酯与氯沙坦干预对其心肌胶原变化的影响

目的:观察大鼠急性心肌梗死(acmemyocardial infarction,AMI)后左心室心肌重构分析和非梗死区Ⅰ、Ⅲ型胶原含量的变化,分别使用螺内酯和氯沙坦以及将两药合用对AMI模型进行干预,探索醛固酮受体拮抗剂和血管紧张素受体阻断剂对AMI后心室重构和胶原增生的影响.方法:将50只雌性SD大鼠随机分为AMI组、螺内酯组、氯沙坦组、联合用药组和假手术组,每组10只,结扎大鼠左前降支建立急性心肌梗死模型.术后8周进行血流动力学测定、病理分析和非梗死区Ⅰ、Ⅲ型胶原含量的测定.结果:AMI组与假手术组相比,左心室舒张末压(LVEDP)、容积、重量和非梗死区Ⅰ、Ⅲ型胶原含量均显著增加(P<0.05);左心室球形指数、左心室内压最大上升和下降速率(±dp/dt/LVSP)均显著降低(P<0.05).螺内酯组与AMI组相比,左心室非梗死区Ⅰ、Ⅲ型胶原含量显著减少(P<0.05),其余各指标差异无统计学意义(P>0.05).氯沙坦组和联合用药组与AMI组相比,LVEDP、左心室实际重量显著降低(P<0.05);左心室容积仅联合用药组有显著降低(P<0.05);而两组的±dp/dt/LVSP显著增加(P<0.05).螺内酯、氯沙坦和联合用药3组与AMI组相比,左心室非梗死区Ⅰ、Ⅲ型胶原含量均显著减少(P<0.05);且3组之间差异无统计学意义(P>0.05).结论:螺内酯能有效抑制AMI左心室非梗死区Ⅰ、Ⅲ型胶原的增生,提示螺内酯可能有改善左心室重构的潜在作用.氯沙坦与螺内酯合用可更有效防治AMI后左心室重构,改善左心室舒张功能.     

Bone marrow-derived stromal cells home to and remain in the infarcted rat heart but fail to improve function: an in vivo cine-MRI study

Basic and clinical studies have shown that bone marrow cell therapy can improve cardiac function following infarction. In experimental animals, reported stem cell-mediated changes range from no measurable improvement to the complete restoration of function. In the clinic, however, the average improvement in left ventricular ejection fraction is around 2% to 3%. A possible explanation for the discrepancy between basic and clinical results is that few basic studies have used the magnetic resonance (MR) imaging (MRI) methods that were used in clinical trials for measuring cardiac function. Consequently, we employed cine-MR to determine the effect of bone marrow stromal cells (BMSCs) on cardiac function in rats. Cultured rat BMSCs were characterized using flow cytometry and labeled with iron oxide particles and a fluorescent marker to allow in vivo cell tracking and ex vivo cell identification, respectively. Neither label affected in vitro cell proliferation or differentiation. Rat hearts were infarcted, and BMSCs or control media were injected into the infarct periphery (n = 34) or infused systemically (n = 30). MRI was used to measure cardiac morphology and function and to determine cell distribution for 10 wk after infarction and cell therapy. In vivo MRI, histology, and cell reisolation confirmed successful BMSC delivery and retention within the myocardium throughout the experiment. However, no significant improvement in any measure of cardiac function was observed at any time. We conclude that cultured BMSCs are not the optimal cell population to treat the infarcted heart.     

Pretreatment of rat bone marrow mesenchymal stem cells with a combination of hypergravity and 5-azacytidine enhances therapeutic efficacy for myocardial infarction

Background and Purpose: The in vivo cardiac differentiation and functional effects of unmodified adult bone marrow mesenchymal stem cells (BMSCs) after myocardial infarction (MI) is controversial. Our previous results suggested that hypergravity promoted the cardiomyogenic differentiation of BMSCs, and thus we postulated that ex vivo pretreatment of BMSCs using hypergravity and 5‐azacytidine (5‐Aza) would lead to cardiomyogenic differentiation and result in superior biological and functional effects on cardiac regeneration of infarcted myocardium. Methods: We used a rat MI model generated by ligation of the coronary artery. Homogeneous rat BMSCs were isolated, culture expanded, and differentiated into a cardiac lineage by adding hypergravity (2G) for 3 days and 5‐Aza (50 lmol/L, 24 h). Rats underwent BMSCs (labeled with DAPI) injection after the infarction and were randomized into five groups. Group A rats received the control medium, Group B rats received unmodified BMSCs, Group C rats received BMSCs treated with hypergravity, Group D rats received BMSCs treated with 5‐Aza, and Group E rats received BMSCs treated with 5‐Aza and hypergravity (n = 6). Results: After hypergravity and 5‐Aza treatment, BMSCs showed positive for the early muscle and cardiac markers GATA‐4, MEF‐2, and Nkx2‐5 with RT‐PCR. We also found that hypergravity could enhance the activities of MEF‐2 via promoting the nuclear export of HDAC5. The frozen section showed that the implanted BMSCs labeled with DAPI survived and angiogenesis was identified at the implantation site. In Groups B, C, D, and E rats, pre‐treated BMSCs colocalized with α‐actinin, and Group E rats showed a significantly larger increase in left ventricular function. Conclusions: The biological ex vivo cardiomyogenic differentiation of adult BMSCs with hypergravity and 5‐Aza prior to their transplantation is feasible and appears to improve their in vivo cardiac differentiation as well as the functional recovery in a rat model of the infarcted myocardium. © 2011 American Institute of Chemical Engineers Biotechnol. Prog., 2011     

In situ delivery of bone marrow cells and mesenchymal stem cells improves cardiovascular function in hypertensive rats submitted to myocardial infarction

This work aimed to evaluate cardiac morphology/function and histological changes induced by bone marrow cells (BMCs) and cultured mesenchymal stem cells (MSCs) injected at the myocardium of spontaneously hypertensive rats (SHR) submitted to surgical coronary occlusion. Female syngeneic adult SHR, submitted (MI) or not (C) to coronary occlusion, were treated 24 h later with in situ injections of normal medium (NM), or with MSCs (MSC) or BMCs (BM) from male rats. The animals were evaluated after 1 and 30 days by echocardiography, histology of heart sections and PCR for the Y chromosome. Improved ejection fraction and reduced left ventricle infarcted area were observed in MSC rats as compared to the other experimental groups. Treated groups had significantly reduced lesion tissue score, increased capillary density and normal (not-atrophied) myocytes, as compared to NM and C groups. The survival rate was higher in C, NM and MSC groups as compared to MI and BM groups. In situ injection of both MSCs and BMCs resulted in improved cardiac morphology, in a more physiological model of myocardial infarction represented by surgical coronary occlusion of spontaneously hypertensive rats. Only treatment with MSCs, however, ameliorated left ventricle dysfunction, suggesting a positive role of these cells in heart remodeling in infarcted hypertensive subjects.     

Cardiomyogenic differentiation-independent improvement of cardiac function by human cardiomyocyte progenitor cell injection in ischaemic mouse hearts

We previously showed that human cardiomyocyte progenitor cells (hCMPCs) injected after myocardial infarction (MI) had differentiated into cardiomyocytes in vivo 3 months after MI. Here, we investigated the short-term (2 weeks) effects of hCMPCs on the infarcted mouse myocardium. MI was induced in immunocompromised (NOD/scid) mice, immediately followed by intramyocardial injection of hCMPCs labelled with enhanced green fluorescent protein (hCMPC group) or vehicle only (control group). Sham-operated mice served as reference. Cardiac performance was measured 2 and 14 days after MI by magnetic resonance imaging at 9.4 T. Left ventricular (LV) pressure-volume measurements were performed at day 15 followed by extensive immunohistological analysis. Animals injected with hCMPCs demonstrated a higher LV ejection fraction, lower LV end-systolic volume and smaller relaxation time constant than control animals 14 days after MI. hCMPCs engrafted in the infarcted myocardium, did not differentiate into cardiomyocytes, but increased vascular density and proliferation rate in the infarcted and border zone area of the hCMPC group. Injected hCMPCs engraft into murine infarcted myocardium where they improve LV systolic function and attenuate the ventricular remodelling process 2 weeks after MI. Since no cardiac differentiation of hCMPCs was evident after 2 weeks, the observed beneficial effects were most likely mediated by paracrine factors, targeting amongst others vascular homeostasis. These results demonstrate that hCMPCs can be applied to repair infarcted myocardium without the need to undergo differentiation into cardiomyocytes.     

Elastin overexpression by cell-based gene therapy preserves matrix and prevents cardiac dilation

After a myocardial infarction, thinning and expansion of the fibrotic scar contribute to progressive heart failure. The loss of elastin is a major contributor to adverse extracellular matrix remodelling of the infarcted heart, and restoration of the elastic properties of the infarct region can prevent ventricular dysfunction. We implanted cells genetically modified to overexpress elastin to re‐establish the elastic properties of the infarcted myocardium and prevent cardiac failure. A full‐length human elastin cDNA was cloned, subcloned into an adenoviral vector and then transduced into rat bone marrow stromal cells (BMSCs). In vitro studies showed that BMSCs expressed the elastin protein, which was deposited into the extracellular matrix. Transduced BMSCs were injected into the infarcted myocardium of adult rats. Control groups received either BMSCs transduced with the green fluorescent protein gene or medium alone. Elastin deposition in the infarcted myocardium was associated with preservation of myocardial tissue structural integrity (by birefringence of polarized light; P < 0.05 versus controls). As a result, infarct scar thickness and diastolic compliance were maintained and infarct expansion was prevented (P < 0.05 versus controls). Over a 9‐week period, rats implanted with BMSCs demonstrated better cardiac function than medium controls; however, rats receiving BMSCs overexpressing elastin showed the greatest functional improvement (P < 0.01). Overexpression of elastin in the infarcted heart preserved the elastic structure of the extracellular matrix, which, in turn, preserved diastolic function, prevented ventricular dilation and preserved cardiac function. This cell‐based gene therapy provides a new approach to cardiac regeneration.     

Transplantation of embryonic stem cells improves cardiac function in postinfarcted rats.

Massive loss of cardiac myocytes after myocardial infarction (MI) is a common cause of heart failure. The present study was designed to investigate the improvement of cardiac function in MI rats after embryonic stem (ES) cell transplantation. MI in rats was induced by ligation of the left anterior descending coronary artery. Cultured ES cells used for cell transplantation were transfected with the marker green fluorescent protein (GFP). Animals in the treated group received intramyocardial injection of ES cells in injured myocardium. Compared with the MI control group injected with an equivalent volume of the cell-free medium, cardiac function in ES cell-implanted MI animals was significantly improved 6 wk after cell transplantation. The characteristic phenotype of engrafted ES cells was identified in implanted myocardium by strong positive staining to sarcomeric alpha-actin, cardiac alpha-myosin heavy chain, and troponin I. GFP-positive cells in myocardium sectioned from MI hearts confirmed the survival and differentiation of engrafted cells. In addition, single cells isolated from cell-transplanted MI hearts showed rod-shaped GFP-positive myocytes with typical striations. The present data demonstrate that ES cell transplantation is a feasible and novel approach to improve ventricular function in infarcted failing hearts.     

不同年龄鼠骨髓干细胞移植治疗心梗后心衰的实验研究

目的：通过对比观察不同年龄鼠骨髓干细胞在体外的生长状态和移入受损心肌后对心肌梗死大鼠心功能的影响,说明年龄对骨髓干细胞的增殖能力和对移植效果的影响。方法：分别分离培养3日龄,1月龄,6月龄,12月龄Wister雄鼠骨髓干细胞,观察细胞生长状态,描记生长曲线。将60只大鼠用结扎冠状动脉前降支的方法制成心肌梗死模型后两周,随机分为三组：Ⅰ组：3日龄组（n=20只）：给予3日龄的5-溴脱氧尿嘧啶（Brdu）标记的鼠骨髓干细胞;Ⅱ组：6月龄组（n=20只）：给予6月龄的Brdu标记的鼠骨髓干细胞;Ⅲ组：对照组（n=20只）：给予培养液。各组均于治疗前及治疗后4周进行心脏超声检查评价心功能改善情况。处死动物取出心脏,进行直接测量后取左心室作石蜡切片,行苏木素-伊红（HE）染色及免疫组化检测,鉴定植入的细胞和心肌、毛细血管再生情况。结果：不同年龄鼠骨髓干细胞培养结果示3日龄及1月龄组增殖能力均高于6月龄及12月龄组,但3日龄与1月龄组之间无统计学差异,12月龄组在原代培养后期即死亡。治疗前超声心动图显示Ⅰ、Ⅱ、Ⅲ组心功能无显著差异（P〉0.05）,治疗之后四周超声心动图检查结果示：Ⅰ、Ⅱ组LVEF、FS、IVST、LVPW和LVESD较治疗前均有明显提高,且显著高于Ⅲ组;Ⅰ组LVEF、FS、IVST、LVPWs和LVESD又明显高于Ⅱ组;Ⅰ、Ⅱ、Ⅲ组LVEDD与治疗前比较无统计学意义。心脏直测结果显示Ⅰ、Ⅱ组的Wh、Wh、Wb、L、I度均较第Ⅲ组有所增加,其中Ⅰ组又明显高于Ⅱ组。免疫组化结果显示：Ⅰ、Ⅱ组于梗死周边均发现Brdu（＋）细胞存在,心肌特异性抗体阳性,且Ⅰ组阳性率明显高于Ⅱ组。毛细血管密度检测结果显示Ⅰ组毛细血管增生情况明显优于Ⅱ组。结论：不同年龄鼠骨髓干细胞的体外增殖能力不同,年龄越小,增殖能力越强。骨髓干细胞移植可以改善心肌梗死后大鼠的心脏功能,增加梗死区毛细血管密度,抑制心室重构,且年龄与移植效果成反比。     

Induced bone marrow mesenchymal stem cells improve cardiac performance of infarcted rat hearts

We investigated whether transplantation of bone marrow mesenchymal stem cells (BMSC) with induced BMSC (iBMSC) or uninduced BMSC (uBMSC) into the myocardium could improve the performance of post-infarcted rat hearts. BMSCs were specified by flowcytometry. IBMSCs were cocultured with rat cardiomyocyte before transplantation. Cells were injected into borders of cardiac scar tissue 1?week after experimental infarction. Cardiac performance was evaluated by echocardiography at 1, 2, and 4?weeks after cellular or PBS injection. Langendorff working-heart and histological studies were performed 4?weeks after treatment. Myogenesis was detected by quantitative PCR and immunofluorescence. Echocardiography showed a nearly normal ejection fraction (EF) in iBMSC-treated rats and all sham control rats but a lower EF in all PBS-treated animals. The iBMSC-treated heart, assessed by echocardiography, improved fractional shortening compared with PBS-treated hearts. The coronary flow (CF) was decreased obviously in PBS and uBMSC-treated groups, but recovered in iBMSC-treated heart at 4?weeks (P?<?0.01). Immunofluorescent microscopy revealed co-localization of Superparamagnetic iron oxide (SPIO)-labeled transplanted cells with cardiac markers for cardiomyocytes, indicating regeneration of damaged myocardium. These data provide strong evidence that iBMSC implantation is of more potential to improve infarcted cardiac performance than uBMSC treatment. It will open new promising therapeutic opportunities for patients with post-infarction heart failure.     

培养于生物降解支架膜内的胚胎干细胞可修复小鼠的梗塞心肌

我们以往的研究表明,直接在心肌梗塞（myocardial infarction,MI）动物的心脏缺血区注射胚胎干细胞（embryonic stemceils,ESCs）可以提高其心肌功能,干细胞组织工程学可以使组织再生、修复。本研究旨在观察将ESCs接种到生物降解膜内并移植到梗塞部位的效果。通过结扎小鼠左冠状动脉制作MI模型,将培养3d的带有小鼠ESCs的聚羟基乙酸膜（polyglycolicacid,PGA）移植到心肌缺血及边缘区表面。实验小鼠分成4组：假手术组、MI组、MI＋PGA组、MI＋ESC组,移植操作8周后检测血流动力学和心肌功能。MI组的血压和左心室功能显著降低。与MI组和MI＋PGA组相比,MI＋ESC组的血压和心室功能显著改善,存活率也显著增高,在梗塞区检测到GFP阳性组织,表明ESCs存活,并可能有心肌再生。以上结果表明,移植生物降解膜内的ESCs可修复小鼠梗塞区心肌细胞并提高心脏功能。将ESCs和生物降解材料联合运用可能为修复受损心脏提供一个新的治疗方法。     

Pretreatment of adult bone marrow mesenchymal stem cells with cardiomyogenic growth factors and repair of the chronically infarcted myocardium

The in vivo cardiac differentiation and functional effects of unmodified adult bone marrow mesenchymal stem cells (MSCs) after myocardial infarction (MI) is controversial. We postulated that ex vivo pretreatment of autologous MSCs using cardiomyogenic growth factors will lead to cardiomyogenic specification and will result in superior biological and functional effects on cardiac regeneration of chronically infarcted myocardium. We used a chronic dog MI model generated by ligation of the coronary artery (n = 30). Autologous dog bone marrow MSCs were isolated, culture expanded, and specified into a cardiac lineage by adding growth factors, including basic FGF, IGF-1, and bone morphogenetic protein-2. Dogs underwent cell injection >8 wk after the infarction and were randomized into two groups. Group A dogs (n = 20) received MSCs specified with growth factors (147 +/- 96 x 10(6)), and group B (n = 10) received unmodified MSCs (168 +/- 24 x 10(6)). After the growth factor treatment, MSCs stained positive for the early muscle and cardiac markers desmin, antimyocyte enhancer factor-2, and Nkx2-5. In group A dogs, prespecified MSCs colocalized with troponin I and cardiac myosin. At 12 wk, group A dogs showed a significantly larger increase in regional wall thickening of the infarcted territory (from 22 +/- 8 to 32 +/- 6% in group A; P < 0.05 vs. baseline and group B, and from 19 +/- 7 to 21 +/- 7% in group B, respectively) and a decrease in the wall motion score index (from 1.60 +/- 0.05 to 1.35 +/- 0.03 in group A; P < 0.05 vs. baseline and group B, and from 1.58 +/- 0.07 vs. 1.56 +/- 0.08 in group B, respectively). The biological ex vivo cardiomyogenic specification of adult MSCs before their transplantation is feasible and appears to improve their in vivo cardiac differentiation as well as the functional recovery in a dog model of the chronically infarcted myocardium.